Satya Das, MD, MSCI, on the Design of a Study of PRRT in Patients With Well-Differentiated NETs

The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Of patients with well-differentiated neuroendocrine tumors (WD-NETs) who were treated with 3 to 4 doses of peptide receptor radionuclide therapy (PRRT), those with a lower clinical score experienced better progression-free survival (PFS) with treatment when compared against those with a higher clinical score, according to results from a study presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.

Of note, this difference in PFS was not observed in patients who did not receive PRRT, indicating there is a predictive utility of clinical score for patients with WD-NETs receiving PRRT with lutetium Lu 177 dotatate (Lutathera).

In an interview with CancerNetwork®, Satya Das, MD, MSCI, assistant professor of Medicine in the department of Medicine of the division of Hematology/Oncology at Vanderbilt University Medical Center, discussed the design of the study.


There’s a lot of uncertainty as to when patients with well-differentiated NETs should get Lutathera or treatment with [peptide receptor radionuclide therapy; PRRT]. The focus of our study was to actually assess and look for answers. It was a cohort analysis that we did. And we looked at 146 patients, 122 at Vanderbilt Ingram Cancer Center and 24 from Rush Medical Center. We had a total of 146 patients included in this cohort.


Das S, Du L, Schad A, et al. A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate. J Clin Oncol. 2021;39(suppl 3). Abstract: 363.

Related Videos
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Related Content